Plus, the mid-cap software stock KeyBanc was wrong about, Goldman Sachs’ semiconductor double-downgrade, and much more.
Dec 20, 2025
Oct 3, 2026
•
1 min read
Plus, a vaccine maker weeks from its pivotal test....
Oct 1, 2026
One stock pick from a top-ranked analyst with an implied upside of 100% or more.
Sep 26, 2026
Plus, a precision medicine company betting on human genetics....